Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )
"2007 was a year of significant clinical, regulatory, pipeline andbusiness accomplishments that helped advance our mission of building a leadingbiopharmaceutical company focused on disorders of the central nervous system,"commented Peter G. Savas, Chairman and Chief Executive Officer of Alseres."Our progress reinforces our confidence in the broad potential of our pipelineand in our leadership in nerve repair and regenerative therapeutics. Ourfocus in 2008 will be on commencing the Phase IIb trial of CETHRIN, partneringour molecular imaging assets and closing collaborations for our regenerativetherapeutics."
Advertisement
About Alseres
Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development oftherapeutic and diagnostic products primarily for disorders in the centralnervous system (CNS). The Company maintains a world-class intellectualproperty position in the field of regenerative therapeutics. The Company'senergy and focus is reflected in several important initiatives. CETHRIN, arecombinant-protein-based drug designed to promote nerve repair after acutespinal cord injury, demonstrated positive interim results in a Phase I/IIaclinical trial. The Company's research and pre-clinical programs include,Inosine for the treatment of spinal cord injury and stroke, Oncomodulin forthe treatment of ocular injury and disease and research programs directed at anumber of regenerative therapies including bone repair. The Company has arobust molecular imaging development program targeting diagnosis ofParkinson's disease and potentially dementia and ADHD. The Company's leadmolecular imaging product candidate is ALTROPANE which is in Phase IIIclinical trials for the diagnosis of Parkinsonian Syndromes includingParkinson's Disease. The Company has research collaborations with HarvardMedical School and Children's Hospital Boston.
Forward-Looking Statements
The foregoing release contains certain forward-looking statements withinthe meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations,beliefs, intentions, goals, strategies, plans or prospects regarding thefuture, including the development and commercialization of ALTROPANE andCETHRIN, the prospects of the Company's CNS and regenerative therapeuticsprograms, the Company's strategies to develop and commercialize axonregeneration technologies and the breadth of the Company's technologies andintellectual property portfolio. Forward-looking statements can be identifiedby terminology such as "anticipate," "believe," "could," "could increase thelikelihood," "estimate," "expect," "intend," "is planned," "may," "should,""will," "will enable," "would be expected," "look forward," "may provide,""would" or similar terms, variations of such terms or the negative of thoseterms. Such forward-looking statements involve known and unknown risks,uncertainties and other factors including those risks, uncertainties andfactors referred to in the Company's Annual Report on Form 10-K for the yearended December 31, 2007 filed with the Securities and Exchange Commissionunder the section "Risk Factors," as well as other documents that may be filedby Alseres from time to time with the Securities and Exchange Commission. Asa result of such risks, uncertainties and factors, the Company's actualresults may differ materially from any future results, performance orachievements discussed in or implied by the forward-looking statementscontained herein. Alseres is providing the information in this press releaseas of this date and assumes no obligations to update the information in thisp
